SCHEMBL6403123

SCHEMBL6403123

CC(=O)N(c1ccccc1)c1ccc(NC(=O)C2CC(=O)N(c3cc(C)ccc3C)C2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.57
ALDH1A1 P00352 6/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
NPSR1 Q6W5P4 2/20 0.55
KDM4E B2RXH2 1/20 0.55
HPGD P15428 1/20 0.55
MCL1 Q07820 1/20 0.55
HIF1A Q16665 1/20 0.55
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA7 P43166 1/20 0.47
CA13 Q8N1Q1 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5843716 0.90 MAPT (0.59) MAPTALDH1A1SMN1; SMN2NPSR1KDM4E
SCHEMBL5842605 0.88 MAPT (0.56) MAPTALDH1A1SMN1; SMN2NPSR1KDM4E
SCHEMBL5842154 0.88 MAPT (0.56) MAPTALDH1A1SMN1; SMN2NPSR1KDM4E
SCHEMBL5842286 0.87 MAPT (0.56) MAPTALDH1A1SMN1; SMN2NPSR1KDM4E
SCHEMBL5841849 0.86 MAPT (0.55) MAPTALDH1A1SMN1; SMN2NPSR1KDM4E
SCHEMBL5844096 0.86 MAPT (0.55) MAPTALDH1A1SMN1; SMN2NPSR1KDM4E
SCHEMBL5842505 0.86 MAPT (0.64) MAPTALDH1A1SMN1; SMN2NPSR1KDM4E
SCHEMBL5844411 0.86 ALDH1A1 (0.72) MAPTALDH1A1SMN1; SMN2NPSR1KDM4E
SCHEMBL5842030 0.86 MAPT (0.64) MAPTALDH1A1SMN1; SMN2NPSR1KDM4E
SCHEMBL5842263 0.85 MAPT (0.54) MAPTALDH1A1SMN1; SMN2NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R MAPT 4395/4885ALDH1A1 3034/4885SMN1; SMN2 3678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.